Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (HCM)
NASDAQ:HCM
HUTCHMED (HCM) Stock Price & Analysis
182 Followers
HCM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.68 - $20.73
Previous Close$17.66
Volume62.84K
Average Volume (3M)131.40K
Market Cap
$3.14B
Enterprise Value$2.35B
Total Cash (Recent Filing)$886.34M
Total Debt (Recent Filing)$86.13M
Price to Earnings (P/E)30.7
Beta1.23
Next Earnings
Jul 31, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.57
Shares Outstanding174,251,254
10 Day Avg. Volume123,415
30 Day Avg. Volume131,396
Standard Deviation0.16
R-Squared0.07
Alpha-0.00570
Financial Highlights & Ratios
Price to Book (P/B)4.26
Price to Sales (P/S)3.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue31.01
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-29.19
Forecast
1Y Price Target
$23.00Price Target Upside30.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
HUTCHMED News
PremiumCompany Announcements
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
PremiumCompany Announcements
New Hope in Advanced Endometrial Cancer Treatment
PremiumCompany Announcements
HUTCHMED’s Savolitinib sNDA Under Review in China
PremiumCompany Announcements
HUTCHMED Advances Sovleplenib Trial in ChinaOwnership Overview
0.00%
Insiders
0.11% Mutual Funds
0.10% Other Institutional Investors
99.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HCM FAQ
What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $10.68 and its highest was $20.73 in the past 12 months.
What is HUTCHMED’s market cap?
Currently, no data Available
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Jul 31, 2024 which is in 102 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Feb 28, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$1.08 by $0.38.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is -$0.26.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,251,250 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of -$0.7 in its last earnings report, beating expectations of -$1.08. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of HUTCHMED?
Among the largest hedge funds holding HUTCHMED’s share is Platinum Investment Management. It holds HUTCHMED’s shares valued at 2M.
---
HUTCHMED Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (30.24% Upside)
$23.00 (30.24% Upside)
Blogger Sentiment
Bullish
HCM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 54.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.20%
12-Months-Change
Fundamentals
Return on Equity
14.81%
Trailing 12-Months
Asset Growth
24.32%
Trailing 12-Months
Company Description
HUTCHMED
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.
---
HCM Company Deck
---
HCM Earnings Call
Q4 2024
0:00 / 0:00
---
HCM Stock 12 Months Forecast
Average Price Target
$23.00
▲(30.24% Upside)
Technical Analysis
Best Analysts Covering HCM
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+27.93%
reiterated a buy rating 2 months ago
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +27.93% per trade.
---